National Bank of Canada
LXEO icon

National Bank of Canada’s Lexeo Therapeutics LXEO Stock Holding History

National Bank of Canada’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1K Buy
+2,462
New +$17.4K ﹤0.01% 2249

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

National Bank of Canada's LXEO Position: Q1 2026 in Review

National Bank of Canada opened a new position in Lexeo Therapeutics (LXEO) in Q1 2026: 2,462 shares worth $14.1K. The stake represents ﹤0.01% of the portfolio and ranks #2249 among its holdings.

139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • National Bank of Canada held 2,462 shares of Lexeo Therapeutics worth $14.1K as of Q1 2026.
  • Lexeo Therapeutics was a new National Bank of Canada position in Q1 2026.
  • Lexeo Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2249 holding.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.